by University of Texas M. D. Anderson Cancer Center Credit: Pixabay/CC0 Public Domain A Phase II clinical trial of poziotinib for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 mutations, led by researchers at The University of Texas MD Anderson Cancer Center, found the drug had significant antitumor activity and...
by H. Lee Moffitt Cancer Center & Research Institute Lung CA seen on CXR. Credit: James Heilman, MD/Wikipedia Immunotherapy has become an important tool in the treatment of lung cancer, especially checkpoint inhibitors that block certain immune checkpoints to allow immune cells to recognize and kill cancer cells. Several checkpoint inhibitors targeting PD-1 and PD-L1 have been approved...
